Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

Bullboard Posts

Post by mrmarket1on Dec 17, 2018 5:44pm

103 Views

Post# 29126406

from website power point presentation may 2018

The Opportunity

1. Large unmet medical need • Market potential in excess of $1.5B US • No competition

2. Value drivers • Completed Phase3 Trial • PMA review mature • Least burdensome trial to be agreed with the FDA within Q3 2018

3. Potential for approval before 2020 • TIGRIS to start in Q4 2018 and to be completed in 1 year

https://www.spectraldx.com/assets/spectral_investor_update_0518.pdf

Bullboard Posts

Investors eye Australian gold mining projects amid promising developments